88 related articles for article (PubMed ID: 8611477)
1. The effect of the GM-CSF/IL-3 fusion protein PIXY321 on bone marrow and circulating haemopoietic cells of previously untreated patients with cancer.
Gheilmini M; Pettengell R; Coutinho LH; Testa N; Crowther D
Br J Haematol; 1996 Apr; 93(1):6-12. PubMed ID: 8611477
[TBL] [Abstract][Full Text] [Related]
2. Effects of in vivo treatment with PIXY321 (GM-CSF/IL-3 fusion protein) on proliferation kinetics of bone marrow and blood myeloid progenitor cells in patients with sarcoma.
Broxmeyer HE; Benninger L; Cooper S; Hague N; Benjamin RS; Vadhan-Raj S
Exp Hematol; 1995 Apr; 23(4):335-40. PubMed ID: 7895781
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of recombinant fusion protein PIXY321 for mobilization of peripheral-blood cells.
Bishop MR; Jackson JD; O'Kane-Murphy B; Schmit-Pokorny K; Vose JM; Bierman PJ; Warkentin PI; Armitage JO; Garrison L; Kessinger A
J Clin Oncol; 1996 Sep; 14(9):2521-6. PubMed ID: 8823331
[TBL] [Abstract][Full Text] [Related]
4. Effect of stem cell factor (c-kit ligand), granulocyte-macrophage colony stimulating factor and interleukin 3 on hematopoietic progenitors in human long-term bone marrow cultures.
Lemoli RM; Gulati SC
Stem Cells; 1993 Sep; 11(5):435-44. PubMed ID: 7694721
[TBL] [Abstract][Full Text] [Related]
5. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
[TBL] [Abstract][Full Text] [Related]
6. Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein versus granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for non-Hodgkin's lymphoma: results of a randomized double-blind trial.
Vose JM; Pandite AN; Beveridge RA; Geller RB; Schuster MW; Anderson JE; LeMaistre CF; Ahmed T; Granena A; Keating A; Fernandez Ranada JM; Stiff PJ; Tabbara I; Longo W; Copelan EA; Nichols C; Smith A; Topolsky DL; Bierman PJ; Lebsack ME; Lange M; Garrison L
J Clin Oncol; 1997 Apr; 15(4):1617-23. PubMed ID: 9193361
[TBL] [Abstract][Full Text] [Related]
7. Modulation of the activity of a human granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein (pIXY 321) by the macrocyclic lactone protein kinase C activator bryostatin 1.
McCrady CW; Li F; Pettit GR; Grant S
Exp Hematol; 1993 Jul; 21(7):893-900. PubMed ID: 7686503
[TBL] [Abstract][Full Text] [Related]
8. Effect of interleukin-3 pretreatment on granulocyte/macrophage colony-stimulating factor induced mobilization of circulating haemopoietic progenitor cells.
Geissler K; Peschel C; Niederwieser D; Goldschmitt J; Hladik F; Fritz A; Ohler L; Bettelheim P; Huber C; Lechner K
Br J Haematol; 1995 Oct; 91(2):299-305. PubMed ID: 8547065
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells.
Winter JN; Lazarus HM; Rademaker A; Villa M; Mangan C; Tallman M; Jahnke L; Gordon L; Newman S; Byrd K; Cooper BW; Horvath N; Crum E; Stadtmauer EA; Conklin E; Bauman A; Martin J; Goolsby C; Gerson SL; Bender J; O'Gorman M
J Clin Oncol; 1996 Jan; 14(1):277-86. PubMed ID: 8558209
[TBL] [Abstract][Full Text] [Related]
10. Neutrophil maturation of CD34+ cells from peripheral blood and bone marrow in serum-free culture medium with PIXY321 and granulocyte-colony stimulating factor (G-CSF).
Smith SL; Bender JG; Berger C; Lee WJ; Loudovaris M; Martinson JA; Opotowsky JD; Qiao X; Schneidkraut M; Sweeney P; Unverzagt KL; Van Epps DE; Williams DE; Williams SF; Zimmerman TM
J Hematother; 1997 Aug; 6(4):323-34. PubMed ID: 9377071
[TBL] [Abstract][Full Text] [Related]
11. Increase in peripheral blood megakaryocyte progenitors following cancer therapy with high-dose cyclophosphamide and hematopoietic growth factors.
Siena S; Bregni M; Bonsi L; Sklenar I; Bagnara GP; Bonadonna G; Gianni AM
Exp Hematol; 1993 Nov; 21(12):1583-90. PubMed ID: 7691640
[TBL] [Abstract][Full Text] [Related]
12. PIXY321 (GM-CSF/IL-3 fusion protein): biology and early clinical development.
Vadhan-Raj S
Stem Cells; 1994 May; 12(3):253-61. PubMed ID: 8075592
[TBL] [Abstract][Full Text] [Related]
13. Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma.
Vadhan-Raj S; Papadopoulos NE; Burgess MA; Linke KA; Patel SR; Hays C; Arcenas A; Plager C; Kudelka AP; Hittelman WN
J Clin Oncol; 1994 Apr; 12(4):715-24. PubMed ID: 8151315
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II trial of PIXY321 to enhance engraftment following autologous bone marrow transplantation for lymphoid malignancy.
Vose JM; Anderson JE; Bierman PJ; Appelbaum FR; Anderson JR; Garrison L; Lebsack ME; Armitage JO
J Clin Oncol; 1996 Feb; 14(2):520-6. PubMed ID: 8636766
[TBL] [Abstract][Full Text] [Related]
15. Mobilization of peripheral blood stem cells by subcutaneous injections of yeast-derived granulocyte macrophage colony stimulating factor: a phase I-II study.
Mangan K; Mullaney M; Klumpp T; Goldberg S; Macdonald J
Stem Cells; 1993 Sep; 11(5):445-54. PubMed ID: 8241955
[TBL] [Abstract][Full Text] [Related]
16. Cytokine-dependent ex vivo expansion of early subsets of CD34+ cord blood myeloid progenitors is enhanced by cord blood plasma, but expansion of the more mature subsets of progenitors is favored.
Ruggieri L; Heimfeld S; Broxmeyer HE
Blood Cells; 1994; 20(2-3):436-54. PubMed ID: 7538350
[TBL] [Abstract][Full Text] [Related]
17. Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin 3 fusion protein, on human tumor colony-forming units taken directly from patients.
Izquierdo MA; Degen D; Raymond E; Caron D; Ortiz V; Banks P; Von Hoff DD
Clin Cancer Res; 1996 Oct; 2(10):1713-6. PubMed ID: 9816121
[TBL] [Abstract][Full Text] [Related]
18. Early suppressive effects of chemotherapy and cytokine treatment on committed versus primitive haemopoietic progenitors in patient bone marrow.
Schwartz GN; Hakim F; Zujewski J; Szabo JM; Cepada R; Riseberg D; Warren MK; Mackall CL; Setzer A; Noone M; Cowan KH; O'Shaughnessy J; Gress RE
Br J Haematol; 1996 Mar; 92(3):537-47. PubMed ID: 8616014
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation.
Crump M; Couture F; Kovacs M; Saragosa R; McCrae J; Brandwein J; Huebsch L; Beauregard-Zollinger L; Keating A
Exp Hematol; 1993 Mar; 21(3):405-410. PubMed ID: 8440338
[TBL] [Abstract][Full Text] [Related]
20. In vitro production of megakaryocytes from PIXY321 versus GM-CSF-mobilized peripheral blood progenitor cells.
Lefebvre P; Winter JN; Rademaker AW; Goolsby C; Cohen I
Stem Cells; 1997; 15(2):112-8. PubMed ID: 9090787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
